

## EVKEEZA<sup>®</sup> is a 60-minute IV infusion every 4 weeks<sup>1</sup>

15 mg/kg      60 minutes      every 4 weeks

Dosage within		Dosage within	
1 vial	<23 kg	4-5 vials	92.1-115 kg
2 vials	23.1-46 kg	5-6 vials	115.1-138 kg
3 vials	46.1-69 kg	6+ vials	138.1+ kg
3-4 vials	69.1-92 kg	Vial size is 345 mg/2.3 mL	

### The dosage for EVKEEZA should be calculated using the patient's weight at 15 mg/kg<sup>1</sup>

The recommended dose is 15 mg/kg administered by intravenous infusion over 60 minutes every 4 weeks. The rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of adverse reactions, including infusion-associated symptoms.

#### Missed dose

If a dose is missed, it should be administered as soon as possible. Thereafter, treatment with EVKEEZA should be scheduled every 4 weeks from the date of the last dose.

#### Overdose

There is no specific treatment for EVKEEZA overdose. In the event of an overdose, the patient should be treated symptomatically, and supportive measures should be instituted as required. For management of a suspected drug overdose, contact your regional poison control centre.

#### Indication:

EVKEEZA (evinacumab for injection) is indicated as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH).

The effects of Evkeeza on cardiovascular morbidity and mortality have not been determined.

### EVKEEZA can be administered without regard to lipoprotein apheresis<sup>1</sup>

Women of childbearing potential should use effective contraception during treatment with EVKEEZA and for at least 5 months after the last dose of EVKEEZA.

Example calculation for the amount of EVKEEZA (mL) recommended if your patient weighs 100 kg

$$\frac{100 \text{ kg (patient's weight)} \times 15 \text{ mg/kg (dose)}}{150 \text{ mg/mL (concentration)}} = 10 \text{ mL (1500 mg) of EVKEEZA required}$$



## Preparation<sup>1</sup>

- 1. Calculate dose and number of vials required.**  
EVKEEZA is preservative-free and is supplied as a single use only. During preparation and reconstitution, a strictly aseptic technique must be used.
- 2. Visually inspect** the medicinal product for cloudiness, discolouration or particulate matter prior to administration. EVKEEZA is a clear to slightly opalescent, colourless to pale yellow solution. Discard the vial if the solution is cloudy or discoloured or contains particulate matter. Do not shake the vial.
- 3. Withdraw the required volume** of EVKEEZA from the vial(s) based on patient's weight, and transfer into an intravenous infusion bag containing sodium chloride 9 mg/mL (0.9%) or dextrose 50 mg/mL (5%) for infusion. Mix the diluted solution by gentle inversion. The final concentration of the diluted solution should be between 0.5 mg/mL and 20 mg/mL. Do not freeze or shake the solution. Discard any unused portion left in the vial.
- 4. Once prepared, administer the diluted solution immediately.** If the diluted solution is not administered immediately, it may be stored temporarily either:
  - under refrigeration at 2°C to 8°C for no more than 24 hours from the time of infusion preparation to the end of the infusion
  - at room temperature up to 25°C for no more than 6 hours from the time of infusion preparation to the end of the infusion.



Please visit [evkeeza.ca](https://evkeeza.ca)  
for more information

or visit [ultracaresupport.ca](https://ultracaresupport.ca) for our  
patient support program.



## Administration<sup>1</sup>

- 1.** If refrigerated, allow the solution to come to room temperature (up to 25°C) prior to administration.
- 2.** Administer EVKEEZA over 60 minutes by intravenous (IV) infusion only through an intravenous line containing a sterile, in-line or add-on 0.2-micron to 5-micron filter.
- 3.** Do not administer EVKEEZA as an IV push or bolus. Do not mix other medicinal products with EVKEEZA or administer concomitantly via the same infusion line.
- 4.** The rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of adverse reactions, including infusion-associated symptoms.
- 5.** Dispose of any unused medicinal product or waste material in accordance with local requirements.

EVKEEZA should only be administered  
by a healthcare professional

### Non-medicinal ingredients:

- L-arginine hydrochloride
- L-histidine
- L-histidine monohydrochloride monohydrate
- L-proline
- Polysorbate 80
- Water for injection

### REFERENCE:

1. EVKEEZA Product Monograph, Ultragenyx Pharmaceutical Inc. 2023.